Glutaminyl Cyclase, Diseases, and Development of Glutaminyl

Discovery of potential scaffolds for glutaminyl cyclase inhibitors: virtual screening, synthesis, and evaluation - ScienceDirect

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Molecules, Free Full-Text

Full article: Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias

is a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM.Glutaminyl Cyclase Inhibitor 1 is compound 23[1].[1]. Li M, et al. Synthesis and

Glutaminyl Cyclase Inhibitor 1

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies

Pyroglutamate Aβ cascade as drug target in Alzheimer's disease

Frontiers Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Glutaminyl cyclase expression and pE-A in Alzheimer's disease

An overview of glutaminyl cyclase inhibitors for Alzheimer's disease

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease—Studies on Relation to Effective Target Occupancy

PDF) Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients